Sharma et al., 2006 - Google Patents
Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BBSharma et al., 2006
- Document ID
- 14208283941110703575
- Author
- Sharma S
- Dominguez A
- Lustgarten J
- Publication year
- Publication venue
- Experimental gerontology
External Links
Snippet
It has been well established that there is a decline in immune function with age resulting in a diminished capacity to respond to infections or tumors. Although many studies have demonstrated the efficacy of autologous dendritic cells (DC) vaccines in stimulating an anti …
- 210000004443 Dendritic Cells 0 title abstract description 61
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB | |
| Linehan et al. | CD25+ CD4+ regulatory T-cells in cancer | |
| Ruby et al. | IL-12 is required for anti-OX40-mediated CD4 T cell survival | |
| US11185586B2 (en) | Allogeneic tumor cell vaccine | |
| WO2003083069A2 (en) | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb | |
| CN113286615A (en) | Combination therapy of microorganisms and immunomodulators for the treatment of cancer | |
| Gao et al. | CD40‐deficient dendritic cells producing interleukin‐10, but not interleukin‐12, induce T‐cell hyporesponsiveness in vitro and prevent acute allograft rejection | |
| Shirota et al. | IL4 from T follicular helper cells downregulates antitumor immunity | |
| Gray et al. | Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies | |
| Alhamarneh et al. | Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? | |
| Lopez et al. | The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines | |
| EP1417300B1 (en) | Process for the maturation of dentritic cells and a vaccine | |
| Ding et al. | IL-7 signaling imparts polyfunctionality and stemness potential to CD4+ T cells | |
| CN112638375A (en) | Increasing immune activity through modulation of post-cellular signaling factors | |
| US20170152506A1 (en) | Inactivation of lymphocyte immunological checkpoints by gene editing | |
| Houtenbos et al. | Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting | |
| CA3182206A1 (en) | Allogeneic tumor cell vaccine | |
| US20160235827A1 (en) | Placental compositions for stimulation of immunity to pd-l1 | |
| Mathieu et al. | Inflammation enhances the vaccination potential of CD40‐activated B cells in mice | |
| Bharadwaj et al. | Recent Developments in the Immunotherapeutic Approaches for Cancer Treatment | |
| US20200297829A1 (en) | Integrative Immunotherapy for Cancer Treatment | |
| US9821044B2 (en) | CD4 T cell vaccine and use thereof | |
| Yan et al. | Killing effect of interleukin-13 receptor alpha 2 (IL-13Rα2) sensitized DC–CTL cells on human glioblastoma U251 cells | |
| Quesnel | Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells? | |
| Linton et al. | T cell function in the aged: Lessons learned from animal models |